Impact of a Guideline-Based Disease Management Team on Outcomes of Hospitalized Patients With Congestive Heart Failure

Abstract
IN THE UNITED STATES, congestive heart failure (CHF) is the leading discharge diagnosis by diagnosis related group, accounting for nearly 1 million hospitalizations and causing 200 000 deaths each year.1 Annual expenditures for CHF are estimated to be $38 billion, of which $23 billion is for inpatient care.2 Medicare expenditures for CHF exceed those for acute myocardial infarction and cancer combined.

This publication has 2 references indexed in Scilit: